Quest Diagnostics Investments, Inc.

Quest Diagnostics Investments Incoporated

Richard E Reitz

Nigel J Clarke

Brett Holmquist

Michael P Caulfield

Sum Chan

Cory E Bystrom

Qibo Jiang

Yanni Zhang

Gloria Kwang-Ja Lee

Gloria Kwangja Lee

W Henry Benner

Ronald M Krauss

Earl Cornell

Patricia J Blanche

Shuguang Li

Amit Ghoshal

Darren A Carns

Shijun Sheng

Mildred M Goldman

Anne Caston-Balderrama

Zhaohui Chen

Michael McPhaul

Kwang-Ja Lee

Anne Caston

Steven W Taylor

Stephen W Taylor

Cory Bystrom

Michael Mcphual

A method of determining the amount of an IGF-I and/or IGF-II protein in a sample using high resolution/high accuracy mass spectrometry includes enriching an IGF-I and/or IGF-II protein in a sample, ionizing an IGF-I and/or IGF-II protein from the sample to generate IGF-I and/or IGF-II protein ions, and determining the amount of IGF-I and/or IGF-II protein ions with high resolution/high accuracy mass spectrometry.

Quantitation of insulin-like growth factor-I and insulin-like growth factor-II with high-resolution mass spectrometry

Provided are methods of detecting the presence or amount of a vitamin D metabolite in a sample using mass spectrometry. The methods generally directed to ionizing a vitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. Also provided are methods to detect the presence or amount of two or more vitamin D metabolites in a single assay.

Methods for detecting vitamin D metabolites by mass spectrometry

The invention relates to the detection of vitamin D metabolites. In a particular aspect, the invention relates to methods for detecting derivatized vitamin D metabolites by mass spectrometry.

Vitamin D metabolite determination utilizing mass spectrometry following derivatization

Methods are provided for determining the amount of an IGF-I and/or IGF-II protein in a sample using high resolution/high accuracy mass spectrometry. The methods generally comprise enriching an IGF-I and/or IGF-II protein in a sample, ionizing an IGF-I and/or IGF-II protein from the sample to generate IGF-I and/or IGF-II protein ions, and determining the amount of IGF-I and/or IGF-II protein ions with high resolution/high accuracy mass spectrometry.

Provided are methods of detecting the presence or amount of the active form of vitamin B6, pyridoxal 5'-phosphate, in a body fluid sample using tandem mass spectrometry coupled with liquid chromatography.

Mass spectrometry method for measuring vitamin B6 in body fluid

Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.

Thyroglobulin quantitation by mass spectrometry

Provided are methods for determining the amount of total thiamine in a body fluid sample using liquid chromatography and mass spectrometry. Total thiamine is converted to free thiamine by treatment with an acid phosphatase prior to thiamine separation and quantification.

Mass spectrometry method for measuring thiamine in body fluid

Provided are methods of detecting the presence or amount of a dihydroxyvitamin D metabolite in a sample using mass spectrometry. The methods generally comprise ionizing a dihydorxyvitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. In certain preferred embodiments the methods include immunopurifying the dihydroxyvitamin D metabolites prior to mass spectrometry. Also provided are methods to detect the presence or amount of two or more dihydroxyvitamin D metabolites in a single assay.

Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry

The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp(a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention.

Lipoprotein analysis by differential charged-particle mobility

Growing community of inventors

San Clemente, CA, United States of America

Richard E Reitz